PLx Pharma initiates endoscopic study of anti-inflammatory drug

This study is a randomized blinded study comparing the rates of gastric and duodenal mucosal damage, measured by endoscopy, between PL 2200 and 325mg aspirin at the preferred over-the-counter dosage used to lower the risk of heart attack and stroke.

The study is a multicenter clinical trial being conducted in the US and is expected to enroll a total of 164 healthy adults between the ages of 50 and 75.

PL 2200 is a molecular complex of aspirin and phosphatidylcholine that is being developed as a gastrointestinal (GI) safer immediate-release aspirin to address the upper GI toxicity of aspirin.